An 225Ac-labeled bis-DOTA compound, complexed on one side with natural lutetium, was studied for anti-HER2 pretargeted radioimmunotherapy and was only transiently taken up by the tumor (17.33 ± 10.77% IA/g at 1 h p.i.)52. This evidence concerns the gene ERBB2 and neoplasm.